<DOC>
	<DOCNO>NCT01252186</DOCNO>
	<brief_summary>This study conduct evaluate impact 91-day extended cycle oral contraceptive compare two 28-day oral contraceptive regimen hemostatic parameter healthy woman .</brief_summary>
	<brief_title>A Multicenter Study Evaluate Effects 91-Day Extended Cycle Oral Contraceptive Hemostatic Parameters Healthy Women</brief_title>
	<detailed_description />
	<mesh_term>Hemostatics</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Levonorgestrel</mesh_term>
	<mesh_term>Desogestrel</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<criteria>Premenopausal , nonpregnant , nonlactating woman age 1840 year old Body Mass Index ( BMI ) ≥18 kg/m² &lt; 30 kg/m² Regular spontaneous menstrual cycle Others dictate FDAapproved protocol Any condition contraindicates use combination oral contraceptives Any history , active , deep vein thrombosis , pulmonary embolism , arterial thromboembolic disease within one year screen Any known genetic component thrombophilia include Factor V Leiden mutation , prothrombin mutation , protein C deficiency , protein S deficience , antithrombin III deficiency Others dictate FDAapproved protocol</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Contraception</keyword>
	<keyword>Hemostasis</keyword>
	<keyword>Blood Coagulation</keyword>
</DOC>